Destination Startup, a collaboration among Front Range research universities and federal laboratories, connects Colorado’s most promising ventures with funding and networking opportunities so they can take the next step toward commercialization.
This year's event — hosted again by Venture Partners at CU Boulder on Feb. 27 — will feature 18 startups from CU Boulder, CU Anschutz, CU Denver, University of Colorado Colorado Springs, Colorado State University, Colorado School of Mines and NIST.
Using algorithms originally developed for financial forecasting, Arpeggio's technology reconstructs the biological network that a drug affects and identifies the genes critical for the success or failure of a drug.
Competing against companies from across the entire state, six CU Boulder startups won a total of $1.5M in grants from the Colorado Office of Economic Development and International Trade (OEDIT)'s Advanced Industries Accelerator (AIA) Program.
Inscripta, a digital genome engineering company spun out of CU Boulder research, has just raised another $125 million in a Series D financing on the heels of launching its revolutionary product, The Onyx™.
A two-year, $2 million National Cancer Institute (NCI) award to Boulder-based startup SuviCa, Inc.—co-founded by CU Boulder and CU Cancer Center investigator, Tin Tin Su—hopes to find drugs that augment the effect of radiation to keep cancer at bay.
The two-day Lab Venture Challenge showcase is the can't-miss event of the year to see CU Boulder's next wave of breakthrough innovations. Register now to hear from the faculty founders of Earable, iFeather and more.
Inscripta, Inc., has announced the launch of the Onyx™ Digital Genome Engineering platform, which enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow.